Verapamil Hydrochloride
Phase 3Small molecule
Mylan Pharmaceuticals IncVerapamil Hydrochloride is one of 56 small molecule programs targeting Keloid. It is currently in Phase 3.
2
Indications
9
Total Trials
2
Active Trials
55
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
105 competitors in Cystic Fibrosis
#DrugCompanyPhaseTrials
1Ibsrela
AArdelyx
Phase 3
Biaxin
AbbViePhase 2
Lamprene
NovartisPhase 2
HSK31858
Haisco Pharmaceutical Group Co., Ltd.Phase 3
Sirturo
WWim Janssens
Phase 2
ELX/TEZ/IVA
Vertex PharmaceuticalsPhase 3
Trikafta
NNottingham University Hospitals NHS Trust
Phase 3
VNZ/TEZ/D-IVA
Vertex PharmaceuticalsPhase 3
VX-121/TEZ/D-IVA
Vertex PharmaceuticalsPhase 3
Verapamil Hydrochloride
Mylan Pharmaceuticals IncPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Lymphoma1 trial
Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Completed·—·Phase 1·NCT03013933·29 enrolled
Keloid1 trial
Cardiovascular1 trial
A Study of the Pharmacokinetic and Pharmacodynamic Responses in Healthy and Altered Human Cardiovascular Systems
Terminated·—·Phase 1·NCT03098680·18 enrolled
Chronic Obstructive Pulmonary Disease1 trial
2 more indications
Cystic Fibrosis1 trial
Unspecified3 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Verapamil Hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company